Abstract
Immunocytokines, antibody-cytokine fusion proteins, have the potential to improve the therapeutic index of cytokines by delivering the cytokine to the site of localized tumor cells using antibodies. In this study, we produced a recombinant anti-programmed death-ligand 1 (PD-L1) scFv, an antibody fragment against PD-L1 combined with a Neo2/15, which is an engineered interleukin with superior function using an E. coli expression system. We expressed the fusion protein in a soluble form and purified it, resulting in high yield and purity. The high PD-L1-binding efficiency of the fusion protein was confirmed via enzyme-linked immunosorbent assay, suggesting the application of this immunocytokine as a cancer-related therapeutic agent.
Highlights
Soluble Expression of aThe immune checkpoint blockades for the treatment of cancer have received increasing attention in novel immunotherapy
The product was ligated to pSrtCys::aPDL1scFv [2], which was amplified by polymerase chain reaction (PCR) using PDL1 vector F (50 -ggggggggttctcatcatca-30 ) and IL2/15 insertion R (50 -tacagtgcatgttcagcatgtaattggatcttcttcttgggactttcgggtgtggcgga-30 ) as primers, using the In-Fusion enzyme
Linker and linked a His-tag purified protein purified protein (His)-tag followed by a Flag-tag-purified protein (Flag)-tag at the 30 -terminal region of the Neo2/15 gene (Figure 2A,B)
Summary
The immune checkpoint blockades for the treatment of cancer have received increasing attention in novel immunotherapy. Antibody against PD-L1 has been approved for application in clinical immunotherapy because of its effective responses in restoring the activity of exhausted T cells to recognize and destroy tumor cells [1]. Several studies have been conducted about the combination of anti-PD-1/PDL-1 antibodies with cytokines to extend the clinical about the combination of anti-PD-1/PDL-1 antibodies with cytokines to extend the clinical effects of PD-1/PD-L1 targeted therapies in the treatment of tumors [10,11,12]. IL-2 or IL-15 enhanced the therapeutic efficacy of the antibody by increasing lytic activity activity against triple-negative breast cancer cells [13].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
